Schizophrenia Research

Schizophrenia is a chronic, debilitating mental disorder affecting 1-2% of the global population. Symptoms are split into two types; 'positive' symptoms, including delusions and hallucinations, and 'negative' symptoms, including anhedonia and lack of motivation. Studies suggest that genetics, early environment, neurobiology, psychological and social processes are important contributory factors; some recreational and prescription drugs appear to cause or worsen symptoms. Several neurobiological alterations in brain structure, physiology and neurochemistry have been documented, along with an ever-increasing list of susceptibility genes.

Schizophrenia Research Products Targets

Products for Schizophrenia Research - Page 65

  1. Cat.No. Product Name Information/Activity
  2. BCC7922 Ro 01-6128 302841-86-7 Ro 01-6128 chemical structure
  3. BCC7921 Ro 67-4853 302841-89-0 Ro 67-4853 chemical structure
  4. BCC6145 Ro 67-7476 Ro 67-7476 is a positive allosteric modulator of mGlu1 receptors. Ro 67-7476 chemical structure
  5. BCC6154 VU 0285683 327056-22-4 VU 0285683 chemical structure
  6. BCC4595 VU 0357121 VU0357121 is a novel positive and highly selective allosteric modulator (PAM) of mGlu5R with EC50 of 33 nM. VU 0357121 chemical structure
  7. BCC6141 VU 0360172 hydrochloride 1309976-62-2 VU 0360172 hydrochloride chemical structure
  8. BCC6159 VU 0360223 1274859-33-4 VU 0360223 chemical structure
  9. BCC7649 VU 1545 890764-63-3 VU 1545 chemical structure
  10. BCC7936 VU 29 890764-36-0 VU 29 chemical structure
  11. BCC6969 (2R,4R)-APDC (2R,4R)-APDC is a selective group II metabotropic glutamate receptors (mGluRs) agonist. (2R,4R)-APDC has anticonvulsant and neuroprotective effects. (2R,4R)-APDC chemical structure

Items 641 to 650 of 709 total